Advertisement

Topics

Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization

10:32 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Quotient Sciences (“Quotient”), the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.. The acquisition...

Other Sources for this Article

For further information, please contact:
Zyme Communications
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com
or
Quotient Sciences
Robin Bodicoat
Marketing Director
Tel: +44 (0)115 931 5102
Email: robin.bodicoat@quotientsciences.com

NEXT ARTICLE

More From BioPortfolio on "Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...